Thermo Fisher Scientific Archives - Medical Design Sourcing

Prominent cell and gene therapy vendors in 2023

[Image courtesy of catalin/Adobe Stock]

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030.

The burgeoning demand in the industry, along with an increasing number of FDA-approved therapies, is also fueling the growth of cell and gene therapy vendors offering tools and services for product development and manufacturing.

The following table includes notable vendors and suppliers active in the call and gene therapy marketplace. This curated selection of companies includes a brief overview of their focus areas.

We have a separate feature focused on companies with prominent cell and gene therapy development efforts.

Company Name Description Notable partnerships Founded He…

100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.

B…

Thermo Fisher grows sales 14% in Q3

Thermo Fisher Scientific posted third-quarter results today that beat the consensus forecast on Wall Street.

The company reported profits of $1.5 billion, or $3.79 per share, on sales of $10.7 billion for the three months ended Sept. 30, for a bottom-line loss of 21.3% on sales growth of 14.4% compared with Q3 2021.

Adjusted to exclude one-time items, earnings per share were $5.08, 26¢ ahead of The Street, where analysts were looking for sales of $9.91 billion.

“We delivered another quarter of excellent financial performance driven by our proven growth strategy and powered by our PPI Business System. Our strategic investments and innovative new product launches are further enhancing our unique customer value proposition and leading to continued share gain,” President and CEO Marc Casper said in a news release. “We saw broad-based strength across our businesses, including our new clinical research business, which is performing very well. Customers are ex…

Thermo Fisher Scientific launches cell therapy manufacturing tech

[Image from Thermo Fisher]

Thermo Fisher Scientific (NYSE:TMO) announced today that it unveiled the Gibco CTS DynaCellect magnetic separation system.

Waltham, Massachusetts-based Thermo Fisher designed DynaCellect to help cell therapy developers easily move from process and clinical development to commercial manufacturing.

The next-generation instrument features cell isolation, activation and depletion along with Dynabeads magnetic beads removal. Thermo Fisher said in a news release that it helps to provide a scalable, flexible, automated and closed system for cell therapy manufacturing.

DynaCellect helps to isolate the right cells and minimize failures in manufacturing. The company expects it to support the commercialization of high-performing therapies and the next class of cell therapy breakthroughs. The system features high throughput capacity and process flexibility.

Thermo Fisher lever…

5 key steps for building a secure cold chain to maintain vaccine and therapeutic stability

Cold chain image courtesy of Thermo Fisher Scientific

COVID-19 vaccine development and rollout were crucial to gaining control of the pandemic. When the success of these efforts became dependent on the ability to maintain lower than typical temperatures during distribution, the importance of reliable and continuous cold chain solutions for mRNA-based formulations was thrust into the spotlight. Beyond pandemic mitigation measures and outside of COVID-19 control, vaccines and therapeutics are increasingly leveraging the power of temperature-sensitive cells, proteins, and nucleic acids in preventing and treating disease. With the pharmaceutical industry shifting toward using biological molecules as medicine, there’s a need to emphasize cold chain logistics and access to innovative, reliable cryogenic solutions.

Pharmaceutical products containing biologically active components often require adherence to special …

Thermo Fisher Scientific completes $1.85B Peprotech acquisition

Thermo Fisher Scientific (NYSE:TMO) announced today that it completed its acquisition of PeproTech for approximately $1.85 billion.

Cranbury, New Jersey-based PeproTech develops recombinant proteins, including cytokines and growth factors, for use in the development and manufacturing of cell and gene therapies, as well as in other broader cell culture applications.

Waltham, Massachusetts-based Thermo Fisher said in a news release that PeproTech’s portfolio of recombinant proteins complements its cell culture media products. The $1.85 billion acquisition was officially completed on Dec. 30, 2021.

Thermo Fisher said it will integrate PeproTech into its life sciences solutions segment as it becomes part of the biosciences business within Thermo Fisher.

“PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by a…

Thermo Fisher completes $17.4B acquisition of PPD

Thermo Fisher Scientific (NYSE:TMO) announced today that it completed its previously announced $17.4 billion acquisition of PPD.

Waltham, Massachusetts-based Thermo Fisher announced in April that it would acquire the company that provides clinical research services to the biopharma and biotech industry. PPD ceased trading on the Nasdaq prior to opening today and will become part of Thermo Fisher’s laboratory products and services segment.

The boards of directors for both companies approved the definitive agreement back in April, which confirmed that Thermo Fisher would buy PPD for $47.50 per share, totaling $17.4 billion, plus the assumption of approximately $3.5 billion of net debt, according to a news release. That represents a premium of approximately 24% to the unaffected closing price of PPD’s common stock on Tuesday, April 13, 2021.

Wilmington, N.C.-based PPD offers clinical research and laboratory services to enable customers to accelerate i…

FDA’s Woodcock reassures about COVID-19 tests, vaccines under Omicron

Acting FDA Commissioner Dr. Janet Woodcock

Acting FDA Commissioner Dr. Janet Woodcock thinks many COVID-19 tests will continue to work with the new Omicron variant — with information coming soon on vaccine efficacy.

In a statement posted yesterday, Woodcock said she thought the agency is well-positioned to work with companies to address the potential impact of viral mutations on COVID-19 tests, therapeutics, and vaccines.

“Getting vaccinated or receiving a booster with one of the currently available vaccines is the best thing that you can do right now (in addition to standard precautions like wearing a mask) to help protect yourself, your family and friends,” Woodcock said.

Discovered in late November in South Africa, the Omicron variant has more than 30 changes to the SARS-CoV-2 spike protein. The variant has enough mutations to raise concerns worldwide, even though it is still un…

COVID-19 test makers say their products also detect Omnicron

[Image from Pixabay]

Abbott, BD, Hologic, PerkinElmer and Thermo Fisher are reassuring the public that their COVID-19 tests detect the Omnicron variant.

Discovered last week in South Africa, the new variant has enough mutations that it has raised concerns worldwide — even though it is still unknown for sure whether the mutations cause greater transmissibility or vaccine evasion. The United States is among the countries restricting travel from southern Africa for the time being, and the CDC is advising all adults to get a booster shot.

Pfizer and Moderna say they’ll create new versions of their vaccines if needed.

Abbott said in a statement on November 27: “We have already conducted an assessment of the Omicron variant, and we’re confident our rapid and PCR tests can detect the virus. While the Omicron variant contains mutations to the spike protein, Abbott’s rapid and molec…

Medtech M&A: The industry’s biggest mergers and acquisitions of 2021

[Image from Jp Valery on Unsplash]

Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more.

Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.

Here are the 10 biggest mergers and acquisitions in medtech in 2021:

Next>>

Thermo Fisher Scientific ticks up on Street-beating Q3 results

Thermo Fisher Scientific (NYSE:TMO) today posted third-quarter results that beat the overall consensus on Wall Street.

The Waltham, Massachusetts–based laboratory supply company reported profits of $1.9 billion, or $4.79 per share, on sales of $9.3 billion for the three months ended October 2, for a bottom-line loss of -1.6% on sales growth of 9.49% compared with Q3 2020.

Get the full story on our sister site, Medical Design & Outsourcing.

Thermo Fisher Scientific ticks up on Street-beating Q3 results

Thermo Fisher Scientific (NYSE:TMO) today posted third-quarter results that beat the overall consensus on Wall Street.

The Waltham, Massachusetts-based laboratory supply company reported profits of $1.9 billion, or $4.79 per share, on sales of $9.3 billion for the three months ended October 2, for a bottom-line loss of -1.6% on sales growth of 9.49% compared with Q3 2020.

Adjusted to exclude one-time items, earnings per share were $5.76, $1.09 ahead of The Street, where analysts were looking for sales of $8.4 billion.

“Our incredibly strong performance in the third quarter demonstrates our proven growth strategy powered by our PPI business system,” president and CEO Marc Casper said in a news release. “We continue to deliver exceptional performance in revenue, earnings and free cash flow. And we are launching innovative new products and expanding our capabilities and capacity to enhance our customer value proposition.”

R…